Peptide research profile

Selank

Also known as TP-7 · Thr-Lys-Pro-Arg-Pro-Gly-Pro

A synthetic tuftsin-derived heptapeptide developed in Russia for anxiety-related research. Human evidence is small and geographically concentrated.

  • Cognitive & neural
Early human evidence2 referencesEducational use

Dosing literacy

Dosing & scaling, explained

The 200 mcg daily row is an injectable calculator preset. Published human Selank work is predominantly intranasal and cannot validate that route or amount. This is educational source context—not a protocol or recommendation.

Scaling framework

How sourced amounts are organized

  1. Starting pointNot clinically established
    No validated titration window

    There is no regulator-approved starting dose for this research use. A low-looking number is not automatically safe.

  2. Recorded preset200 mcg / day
    Calculator library reference

    This is the range represented in the in-app protocol library. It describes the source record; it does not validate the regimen.

  3. Higher exposureNo injectable ceiling established
    Risk and uncertainty increase

    Higher exposure is not established as more effective. Human pharmacokinetic and long-term safety data may be absent.

Drug amount and device markings are different quantities. The calculator converts mass into volume, syringe units, or pen clicks.

Schedule literacy

Patterns described in source material

  • Daily in the recorded preset

    The cadence represented by the recorded calculator presets.

  • Intranasal courses in regional clinical studies

    Published experiments may use a different route, formulation, timing, or population and should not be treated as interchangeable.

  • No universal schedule

    No single schedule has been validated across products or research contexts.

Clinical context

Limited human evidence exists, but it does not establish the in-app injectable regimen.

Research best practices

Storage, handling and interpretation

Lyophilized material

Keep cold, dry, and protected from light according to the manufacturer certificate or validated lab SOP.

After reconstitution

Use sterile technique, refrigerate as validated, and avoid repeated freeze–thaw cycles.

Traceability

Record lot, concentration, preparation date, and the identity/purity documentation used by the lab.

Research orientation

What researchers are exploring

These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.

  • 01

    Anxiety symptoms

    Small Russian comparative studies examine generalized anxiety and neurasthenia.

  • 02

    GABAergic signaling

    Animal transcript studies report changes in genes involved in inhibitory neurotransmission.

  • 03

    Enkephalin metabolism

    Clinical and biochemical work explores enkephalin-related mechanisms.

  • 04

    Stress and cognition

    Preclinical studies examine behavior, learning, and stress adaptation.

Evidence map

What the current evidence can support

Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.

  • Human

    Small active-comparator study

    A 62-patient study compared Selank with medazepam and reported similar anxiety-scale improvement.

  • Animal

    GABA-related gene expression

    Rat frontal-cortex studies found broad transcriptional changes after Selank administration.

  • Review

    Independent replication gap

    Modern, preregistered, multicenter trials outside the originating network are lacking.

Recorded protocol library

Amounts recorded for Selank

These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.

  • 01

    Dose · lower endpoint

    100 mcg

    Sign in for schedule, duration and source context.

  • 02

    Recorded reference

    200 mcg

    Sign in for schedule, duration and source context.

  • 03

    Dose · upper endpoint

    500 mcg

    Sign in for schedule, duration and source context.

Technical reference

Identity, limitations and unknowns

Molecular profile

Class
Tuftsin-derived synthetic heptapeptide
Sequence
TKPRPGP
Amino acids
7
Approx. MW
751.9 Da
Origin / design
Extended analogue of the immunomodulatory peptide tuftsin

Important limitations

  • The main clinical report is small, regionally concentrated, and not a modern large placebo-controlled trial.
  • Regulatory status differs internationally and no FDA-approved product exists.
  • A calculator preset is a recorded research convention, not a recommendation or evidence of clinical benefit.
  • Identity, purity, sterility, and stability can vary substantially outside regulated manufacturing.
  • Route, formulation, and population can make results from one study inapplicable to another use.

Curated sources

2 curated references

  1. Efficacy and possible mechanisms of action of Selank in generalized anxiety disorders and neurastheniaZhurnal Nevrologii i Psikhiatrii · 2008 · Human
  2. Selank administration affects the expression of genes involved in GABAergic neurotransmissionFrontiers in Pharmacology · 2016 · Animal

Related profiles